Prostate Cancer

Transrectal ultrasound-guided prostate biopsy is associated with a rising rate of hospitalization for urinary tract infection, new study results indicate.

Presentations of phase III data at the American Society of Clinical Oncology annual meeting in Chicago further support the conclusion that the oral androgen receptor inhibitor enzalutamide (XTANDI) addresses an unmet therapeutic need for metastatic castration-resistant prostate cancer in the pre-chemotherapy setting.

A recent study confirms that treatment choices for localized prostate cancer are not stagnant but continue to evolve, writes Leonard G. Gomella, MD.

The question of what role urologists should play in managing hormone-resistant prostate cancer is "controversial," says Kenneth Jacobsohn, MD.

Use of surgery has increased steadily among all men with clinically localized prostate cancer, and in those with low-risk disease, brachytherapy utilization has declined.

A significant number of older men with limited life expectancy continue to undergo routine prostate cancer screening, researchers say.

Drugs and devices in the pipeline form Clarus Therapeutics, Nymox Pharmaceutical, Bioniche Life Sciences, Repros Therapeutics, BioLight Life Sciences Investments/Micromedic Technologies, Cubist Pharmaceuticals, Takeda Pharmaceutical, H. Lundbeck A/S, Transplant Genomics, Orion, Bayer, and Roche.

Recently published data from the European Randomised Study of Screening for Prostate Cancer (ERSPC) indicate that screening for prostate cancer could reduce deaths from the disease by about one-fifth.

Two independent published trials have validated the performance of an epigenetic test that could provide physicians with a better tool to help eliminate unnecessary repeat prostate biopsies.

A genomic tool for prostate cancer appears to provide physicians and patients with improved decision making about the use of radiation therapy after radical prostatectomy.

A new study showing a survival benefit of more than 1 year with a chemotherapy-hormonal therapy combination given prior to castration resistance is being hailed by a leading prostate cancer expert as possibly representing a “new standard” in care.

Prospective, long-term follow-up in a large cohort of hypogonadal men treated with testosterone replacement therapy (TRT) provides no evidence that TRT increases the risk for prostate cancer.

The “embarrassment of riches” of therapeutic options for advanced prostate cancer fortunately continues, encouraging us all to strive for lessening the incidence and impact of prostate cancer-specific mortality.

Diagnosing physicians-urologists in particular-significantly influence decision making in men with low-risk prostate cancer as well as the type of treatment selected, according to researchers from The University of Texas MD Anderson Cancer Center in Houston.

In our “Best of AUA” report, Urology Times’ editors and writers present the AUA annual meeting’s take-home messages in 15 therapeutic areas.

Androgen deprivation therapy provides no survival benefit in older men with localized prostate cancer at 15 years, newly published research shows.

Manish A. Vira, MD, presents the take home messages on minimally invasive surgery from the AUA annual meeting in Orlando, FL.

Jesse D. Sammon, DO, presents the take home messages on outcomes analysis from the AUA annual meeting in Orlando, FL.

K.C. Balaji, MD, presents the take home messages on basic science research from the AUA annual meeting in Orlando, FL.

Michael C. Gong, MD, PhD, presents the take home messages on prostate cancer from the AUA annual meeting in Orlando, FL, including new findings about enzalutamide (XTANDI).

New urology products and services from Symtelligence Medical Informatics, LABORIE, Metamark Genetics, the MediSafe Project, and Olympus

Robot-assisted radical prostatectomy may be associated with improved surgical margin status compared to open radical prostatectomy for men with intermediate-risk and high-risk prostate cancer, according to a study presented at the AUA annual meeting in Orlando, FL.

Men with prostate cancer who are treated with external beam radiation therapy are at an increased risk for cancer of the bladder and rectum 10 years or more after their prostate cancer diagnosis, according to an analysis using data from the Surveillance, Epidemiology, and End Results program.

The majority of urologists and radiation oncologists feel active surveillance is an effective and underused modality for managing low-risk prostate cancer; however, few of these specialists would recommend this strategy to patients, according to recent survey results.

Salvage extended pelvic lymph node dissection (ePLND) may be highly beneficial for selected prostate cancer patients with biochemical recurrence and clinically recurrent nodal disease, say German researchers.